Jupiter Life Line Hospitals’ IPO, under the ‘Jupiter’ brand, commenced today with a total offering of Rs 869.08 crore, having already secured Rs 260.72 crore from 39 anchor investors at Rs 735 per share. In the grey market, the IPO exhibits a robust 29.66% premium, indicating investor optimism. However, financial experts stress the importance of evaluating the company’s fundamentals and performance over market sentiment.
Jupiter Hospital IPO’s Robust Market Debut and Investment Considerations for Prospective Investors
The Jupiter Hospital IPO subscription window will remain open until September 8, with investors able to participate in the offering priced between Rs 695 and Rs 735 per share, in lots of 20 shares. The allocation of shares is divided into halves for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 35% for retail investors. Following a successful IPO, the allotment of shares is set to be finalized on September 13, with listing on both BSE and NSE scheduled for September 18.
Jupiter Life Line Hospitals, recognized for multi-specialty tertiary and quaternary healthcare, operates hospitals in Thane, Pune, and Indore, collectively offering 1,194 beds and employing 1,306 doctors, including specialists, physicians, and surgeons. The company’s financial trajectory showcases a net loss of Rs 2.30 crore in the financial year 2021, followed by a remarkable turnaround with a net profit of Rs 51.13 crore in 2022, and further growth to Rs 72.91 crore in the subsequent fiscal year.
